MASH awareness survey completed: no treatment, just insights
NCT ID NCT07201831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal was to gather information for future research, not to test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novo Nordisk Investigational Site
Plainsboro, New Jersey, 08536, United States
-
Novo Nordisk Investigational Site
Mississauga, Canada
-
Novo Nordisk Investigational Site
Puteaux, France
-
Novo Nordisk Investigational Site
Mainz, Germany
-
Novo Nordisk Investigational Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Seaweed extract may tackle fatty liver Disease—A trial puts it to the test
- Can Weight-Loss surgery rewire the Liver's energy engine?
- Wheat sensitivity linked to fatty liver? a new study investigates
- Could a common sugar fuel liver damage?
- Could a common b vitamin tame fatty liver?